Results 81 to 90 of about 86,485 (257)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports

, 2011
Mahmud Mahamid1,3, Kalman Paz3, Rifaat Safadi1,21Liver Unit, Holy Family Hospital, Nazareth, Israel; 2Hadassah Medical Center, 3Shaare Zedek Medical Center, Jerusalem, IsraelAbstract: Elevation of liver enzymes in patients with rheumatoid arthritis ...
Paz K, Safadi R, Mahamid M
core  

Intelligent Programmable Membrane Nanosponge for Early Virus Blocking

Advanced Science, EarlyView.
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen, Zhuojun He, Huimin Guo, Min Shi, Ruijing Liang, Lanlan Liu, Yeneng Dai, Qi Zhao, Ke Liu, Yang Zhou, Yang Zhang, Jian Ren, Bin Ju, Quan Fang, Zhaozhen Li, Pengfei Zhao, Mingbin Zheng, Lintao Cai   +17 more
wiley   +1 more source

Herpes Zoster After Tocilizumab Therapy in COVID-19 Survivor: A Case Report

Acta Medica Indonesiana, 2022
The COVID-19 pandemic has become a concern for the world community. However, despite abundant attempts taking place, there is currently no definitive therapy for COVID-19 yet.
Suwenny Suwenny, Sahat Halim
doaj   +2 more sources

Immune Modulatory Therapy for Severe Dengue Hemorrhagic Fever in a Patient With Mitochondrial Complex I Deficiency: A Case Report

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Dengue virus (DENV) poses a serious global health challenge, particularly in cases of dengue hemorrhagic fever (DHF). Patients with preexisting mitochondrial disorders may be at increased risk for complications due to the specific impact of DENV on mitochondrial‐dependent cellular processes and immune function.
Audra N. Iness, Ameya S. Walimbe, Emily R. Strouphauer, Michio Hirano, Alejandro D. Iglesias, Valentina Emmanuele, Caitlin C. Griffin, Sheldon L. Kaplan, William A. Gomes, Karen K. Moeller, Stephen F. Kralik, Fernando Scaglia   +11 more
wiley   +1 more source

Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

Scientific Reports
Respiratory pandemics like COVID-19 continued to strain healthcare systems worldwide. Numerous antiviral, antimalarial, and anti-inflammatory treatments were administered to many patients to pursue effective therapeutics.
Abbas Al Mutair, Saad Alhumaid, Gasmelseed Y. Ahmad, Ali A. Rabaan, Sameer A. Alkubati, Hamdan Albaqawi, Awatif M. Alrasheeday, Bushra Alshammari, Kawther Alsaleh, Richard Mottershead, Muhammad Daniyal, Awad Al-Omari   +11 more
doaj   +1 more source

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

, 2012
Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba
Nishimoto N, Tomiita M, Murakami M
core  

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

, 2020
Stephanie Si,1,2 David T Teachey1,2 1Children’s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA; 2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USACorrespondence: Stephanie
Teachey DT, Si S
core  

Case reports Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab

, 2015
A case report of a boy with juvenile idiopathic arthritis since the age of 2 years, generalized onset, complicated by nephrotic syndrome due to secondary type A amyloidosis is presented.
Małgorzata Kwiatkowska, Ewa Jednacz, Lidia Rutkowska-Sak   +2 more
core   +1 more source

Intestinal disease secondary to tocilizumab.

, 2022
20.500.12530/87913It is presented a case study of intestinal affectation on a patient under tocilizumab treatment for giant cell ...
Suárez-Ferrer, Cristina, Siljeström Berenguer, Carlota, Bonilla, Gema   +2 more
core   +1 more source

Construction and evaluation of a chronic arthritis animal model induced by persistent activation of toll‐like receptors via lipopolysaccharide stimulation

Animal Models and Experimental Medicine, EarlyView.
We constructed a novel systemic juvenile idiopathic arthritis mouse model (LC) by introducing sustained TLR4 activation into the collagen‐induced arthritis model. The LC model effectively recapitulates human sJIA‐like systemic inflammation while revealing a critical dissociation between systemic immune activation and joint damage.
Fengming Li, Qiang Luo, Xinglin Wu, Yuxiao Chen, Xuemei Tang   +4 more
wiley   +1 more source